Access Vascular, Inc.

Our company was founded to solve the significant yet unmet needs in venous access. After shadowing physicians and learning about the challenge that thrombosis presents to venous access, our founders set off to develop a new, superior material to the polyurethane used in conventional venous catheters. We plan to expand our material platform to potentially provide long-term infection protection and minimize vessel trauma during catheter insertion.  In 2018, we secured FDA clearance on our first product, a peripherally inserted central catheter (PICC) which was found to be effective in reducing thrombosis accumulation*. That’s just the beginning: we are developing a comprehensive suite of venous access devices, including peripheral venous catheters, dialysis catheter and ports.  We are a privately held company based in Bedford, MA. Our headquarters consists of a 7,100 square foot facility that includes state-of-the-art laboratory and manufacturing spaces. We employ approximately 20 employees and have begun commercial sales of our first product.  *Data on file at Access Vascular. Reduction of thrombus accumulation was evaluated using in vitro and in vivo models. Pre-clinical in vitro/in vivo evaluations do not necessarily predict clinical performance with respect to thrombus formulation.

Quality Policy

Access Vascular is committed to providing our customers with the highest quality intravascular products that meet or exceed expectations. Access Vascular commits to comply with the necessary requirements and regulations through the regular maintenance of an effective quality system and seeks to continuously improve its products.